SuperX
  1. Home
  2. Stocks
  3. ABOT

ABOT Abbott Laboratories (Pakistan) share price

Abbott Laboratories (Pakistan) in one paragraph

As of 20 Nov 2026, the Abbott Laboratories (Pakistan) (ABOT) share price is Rs 1,013.28 (+0.42% on the day). Over the last year it has moved −5.91%. Its market capitalisation is about Rs 99.2B. The trailing dividend yield is 3.95%. PSX lists it as Shariah-compliant. Abbott Laboratories (Pakistan) is in the Pharmaceuticals sector, and is a KSE-100 member. Its last cash dividend was Rs 40.00 a share, ex-date 22 Apr 2026.

Close · 20 Nov 2026 · Pakistan Stock Exchange · Vol 7.6K

Rs 1,013.28

+4.26 (+0.42%)

Chart ABOT in SuperX Apex

52-week low821.00

52-week high1,274.00

Daily closes from the Pakistan Stock Exchange, to 20 Nov 2026.
ABOT · close, 20 Nov 2025 to 20 Nov 2026 −5.92% · 249 sessions

Rs 1,013.28 20 Nov 2026

20 Nov 2025 H 1,257.76 · 8 Jan 2026 L 836.92 · 9 Mar 2026 20 Nov 2026

DEx-dividend day: the price falls by about the payoutRResults filed

A period starts at the last close on or before the same date one week, one, three or six months, or one, three or five years earlier, and ends at the latest close drawn. The year to date starts at the last close of the previous year.

1 week
+1.33%
1 month
+8.30%
3 months
+12.05%
6 months
+20.02%
Year to date
−3.51%
1 year
−5.91%
3 years
+147.08%
5 years
+32.87%
Since Sep 2016
+27.46%

Daily closes from the Pakistan Stock Exchange, to 20 Nov 2026.

Price only, from the close of 20 Nov 2025, Rs 1,076.96, to the close of 20 Nov 2026, Rs 1,013.28: −5.92%. The 1Y figure above, −5.91%, starts earlier, from the last close on or before 20 Nov 2025, and ends on the latest close. Neither figure counts dividends.

Last price
Rs 1,013.28
20 Nov 2026
Change on the day
+0.42%
+Rs 4.26
Market cap

Market cap

What the whole company costs at today's price.

How it's worked out

Share price multiplied by every share in issue.

How to read it

It is the company's size, not its value. A big number does not mean the price is high against earnings, and a small one does not mean it is low — that is what the ratios below are for.

Rs 99.2B
as of 20 Nov 2026
Price per rupee earned

Price per rupee earned

Rupees you pay for each rupee the company earned last year.

How it's worked out

Share price divided by earnings per share over the last twelve reported months.

How to read it

Lower only means something against something — the same company's history, its sector, or the market. On its own this ratio says very little, and it is blank when a company lost money.

10.68×
price-to-earnings · unconsolidated, the last twelve months (PSX screener)
Dividend yield

Dividend yield

Cash paid out over the last year as a percentage of today's price.

How it's worked out

Dividends per share over twelve months divided by the share price.

How to read it

A very high yield is often a warning, not a gift: it usually means the price fell. Check the payout ratio next to see whether earnings actually cover it.

3.95%
Rs 40.00/sh last 12m ÷ Rs 1,013.28
Earnings per share
Rs 81.37
the year to 31 Dec 2025
52-week range
821.00 – 1,274.00
the price is at 42% of the range
Day range
1,000.01 – 1,015.00
prev close 1,009.02
Volume
7.6K
shares, this session
Avg volume (30d)

Average volume

Shares changing hands on a typical day.

How it's worked out

The mean daily volume over thirty sessions.

How to read it

Shares, not rupees — a million shares of a Rs 3 stock is a small market. "Traded per session" is the version in money.

14.1K
9 more figures
Beta vs KSE-100

Beta

How hard it swings when the market swings.

How it's worked out

The slope of this stock's daily returns against the KSE-100's, over a year of sessions.

How to read it

1.0 moves with the market, 1.5 exaggerates it by half, below 1 is steadier. It says nothing about direction, only about size.

0.78
1 year of daily closes
Book value / share

Book value per share

The accounting value of one share, in rupees.

How it's worked out

Total equity divided by shares outstanding — what each share would be worth if the company sold everything at balance-sheet value and paid off every debt.

How to read it

The floor under a share price, loosely. It ignores brands, people and future profits, so a good business trades well above it and a broken one below.

Rs 323.03
accounts to 31 Dec 2025
Shares outstanding

Shares outstanding

Every share the company has issued.

How it's worked out

The share count in the company's own filings, including the blocks nobody trades.

How to read it

Divide any per-share figure by this. It is larger than the free float on almost every PSX name, because sponsors and the government own shares that never reach the market.

97.9M
Free float

Free float

The shares that can actually be bought and sold.

How it's worked out

Total shares minus the blocks held by sponsors, the government and other locked-in holders, as the exchange reports them.

How to read it

The float, not the market cap, is what sets how easily a real position can be built or unwound.

21.2M
21.6% of shares
Last dividend
Rs 40.00
ex-date 22 Apr 2026
Last results filed
27 Oct 2026
Index member
All-Share, KMI All-Share, KSE-100
Shariah
Compliant

Figures as of 20 Nov 2026.

What changed for ABOT

Latest · to 20 Nov

  • 20 NovClosed 1,013.28, +0.42%. Volume 7,648, 0.6 times the average of the 30 sessions before it, 13,634.
  • 27 OctQuarter ended 30 Sep 2026: earnings per share Rs 25.99, sales Rs 20.6 bn, up 39.6% on the same quarter a year before. All results
  • 2 NovTrend read changed to leaning up: above the 50-day average; up 11.3% over 3 months; up 7.6% over 1 month.
  • NextAnnual results (to 31 Dec 2026) expected 2 Feb 2027 – 16 Mar 2027, a projection. An estimate from the dates of the last 6 filings.

Closes and notices: PSX. Trend read: SuperX, from daily closes. Volume: against the average of the 30 sessions before the last. Next results: an estimate from the dates of the last 6 filings. Not advice.

What SuperX wrote about ABOT

SuperX holds no shares in Abbott Laboratories (Pakistan).

  1. The price rose 0.42% on 20 Nov, while the sector median was 0.0%. Volume was 0.48 times the usual.

  2. The annual results cover the period ending 31 Dec. Last year they were filed on 16 Mar.

  3. The price is 19.44% below the 52-week high. In the past year the price fell 5.91%.

Written by SuperX’s analyst desk from SuperX’s own figures, from the close of 20 Nov 2026. Each number was checked against those figures. Not advice.

01Returns1 year −5.91%

ABOT in figures

As of 20 Nov 2026. Each figure states its period, its basis and its source. Not advice.

Return over time

Returns to the price at 16:45 on 20 Nov 2026. The sector median runs to the close of 20 Nov 2026, over 14 companies.

Change in price since 21 Nov 2025, weekly closes, each line starting at zero

Price only, weekly closes, 21 Nov 2025 to 20 Nov 2026.
MethodEvery line starts at 0% on 21 Nov 2025. The index line is the KSE-100 price index (KSE100PR), which leaves dividends out, so both lines are price only. The table below gives the return with dividends. Source: PSX closes and the KSE100PR index.

Return with dividends over each window, against the KSE-100

Return with dividends, not reinvested. The windows of a group share one scale; the two groups do not. Source: PSX closes and payout notices.
OverPrice onlyWith dividendsKSE-100Sector median
1 monthfrom the close of 20 Oct 2026, Rs 935.61+8.30%+8.30%+7.41%+3.24% (10 companies)
3 monthsfrom the close of 20 Aug 2026, Rs 904.28+12.05%+12.05%+0.45%−4.13% (10 companies)
6 monthsfrom the close of 20 May 2026, Rs 844.27+20.02%+20.02%+7.61%−4.89% (10 companies)
Since 1 Januaryfrom the close of 31 Dec 2025, Rs 1,050.14−3.51%+0.30%dividends Rs 40.00+1.91%−16.14% (10 companies)
1 yearfrom the close of 20 Nov 2025, Rs 1,076.96−5.91%−2.20%dividends Rs 40.00+8.87%−15.80% (10 companies)
3 yearsfrom the close of 20 Nov 2023, Rs 410.10+147.08%+159.27%dividends Rs 50.00+210.77%+130.02% (9 companies)
5 yearsfrom the close of 19 Nov 2021, Rs 762.60+32.87%+44.02%dividends Rs 85.00+281.55%+74.12% (9 companies)

Price only: closes adjusted for bonus and rights issues, to the latest price. With dividends: adds cash dividends, not reinvested. The KSE-100 figure reinvests dividends. Source: PSX closes and payout notices.

02Value10.68× per rupee earned

Key figures against the sector

Against sector and market

Each group has its own scale. Medians count only companies with the figure (yield: payers). "Above": share of other listed companies lower.
Price per rupee earned10.68×sector median 12.46× (12 companies) · 14.3% below the sector median · above 2 of 12 sector companiesunconsolidated, the last twelve months (PSX screener)
Dividend yield3.95%7 of 14 sector companies pay a dividend · median over payers only: 5.12% (7 companies) · 22.8% below the sector median · above 3 of 7 sector companiesCash dividends of the last 12 months over the price
Net profit as a share of sales10.57%sector median 9.41% (13 companies) · 12.3% above the sector median · above 7 of 13 sector companiesLatest filed year, to 31 Dec 2025, company accounts
Sales growth a year, over 3 years15.25%sector median 16.35% (11 companies) · level with the sector median · above 4 of 11 sector companiesFiled sales, year to 31 Dec 2022 to year to 31 Dec 2025, company accounts
Move with the KSE-100 (beta), 1 year0.78sector median 1.06 (14 companies) · 26.6% below the sector median · above 3 of 14 sector companiesDaily price changes over the year to 20 Nov 2026, against the KSE-100
Return over 1 year, with dividends-2.20%sector median -10.59% (14 companies) · 79.2% above the sector median · above 10 of 14 sector companiesPrice change over one year plus cash dividends, not reinvested
Earnings per share growth a year, over 3 years38.41%sector median 21.11% (9 companies) · 82.0% above the sector median · above 5 of 9 sector companiesFiled earnings per share over three years, on today’s share count, company accounts
Gross profit as a share of sales35.08%Latest filed year, company accounts

A figure is called above or below the sector median when the gap is more than 10%.

Compared with the 14 other companies in its PSX sector, Pharmaceuticals. A sector median is left out when no other company in the sector has the figure.

The same ratio on other definitions

ABOT earnings per share: Rs 81.37 · unconsolidated · the year to 31 Dec 2025 · PSX company page

Price per rupee earned, our own: 12.45 (1,013.28 on 20 Nov 2026 over 81.37, unconsolidated, the year to 31 Dec 2025) · the PSX screener's figure: 10.68

The valuation in context

How does ABOT’s valuation compare with its sector?

From filed accounts and ABOT's price history · as of 20 Nov 2026

One ratio on its own says little. These put ABOT's valuation next to its sector and the market, its dividend next to its earnings, its quoted price next to how much of it actually trades, and its return next to the risk taken to earn it.

Valuation in context

Earnings yield

Earnings yield

What the business earns on its price, so it lines up with a savings rate.

How it's worked out

Earnings per share divided by the share price — the price-to-earnings ratio turned over.

How to read it

If a company earns 17% against its price and a T-bill pays 12%, you can finally compare the two. It is what the business earns, not what it pays you — the dividend yield is the cash that reaches your account.

9.36%
Price to sales

Price to sales

What you pay for each rupee of revenue.

How it's worked out

Market cap divided by the latest reported annual sales.

How to read it

Useful where earnings are negative or lumpy and a price-to-earnings ratio says nothing. It ignores costs entirely, so a low number does not mean a good business.

1.32×
Price, earnings and growth together

Price, earnings and growth together

The price per rupee earned, measured against how fast earnings are growing.

How it's worked out

The price-to-earnings ratio divided by the three-year growth rate of earnings per share.

How to read it

Under 1 is the old rule of thumb for a multiple that growth justifies. Blank when earnings are shrinking, because the ratio flips sign and stops meaning anything.

0.28
vs the KSE-100's own multiple

vs the KSE-100's own multiple

Whether a rupee of this company's earnings costs more or less than the market's.

How it's worked out

Its price-to-earnings ratio against the KSE-100's, which we compute as the total market cap of the index over the total earnings of its members.

How to read it

−30% means it trades thirty percent below the market's multiple. Below the market is a question, not an answer: often the market is right about why.

+34%
vs KSE-100, one year

vs KSE-100, one year

How far ahead of or behind the market it finished.

How it's worked out

Its one-year return minus the KSE-100's, in percentage points.

How to read it

"Up 12%" means one thing when the index rose 20% and another when it fell. Unlike alpha, this ignores how much market risk was carried to get there.

-8.3 pts

It costs less for each rupee earned than 81% of the pharmaceuticals companies with reported earnings, and it yields more than 36% of them.

Income & quality

Dividend per share, 12 months

Dividend per share

The actual rupees per share paid out over the last twelve months.

How it's worked out

Every cash dividend with an ex-date in the last year, added up from the exchange's own book-closure notices.

How to read it

Multiply by your shares and that is the cash that reached you, before tax. Bonus shares are not in here — they are not money.

Rs 40.00
Cash dividends paid, 12 months

Dividends paid

How many times it paid cash in the last twelve months.

How it's worked out

A count of cash dividends with an ex-date in the last year.

How to read it

Four usually means a quarterly payer, one means an annual one. A steady cadence is worth more to an income investor than a single big number.

1
Payout ratio

Payout ratio

How much of its profit the company hands to shareholders.

How it's worked out

Dividend per share over the last year divided by earnings per share.

How to read it

Above 100% means it paid out more than it earned — possible from reserves for a year, not for five. Low means it is keeping money to reinvest, which is not automatically bad.

49%
Dividend cover

Dividend cover

How many times over the earnings could pay the dividend.

How it's worked out

Earnings per share divided by dividend per share — the payout ratio the other way round.

How to read it

Above 2 is comfortable. Below 1 means the dividend is coming from somewhere other than this year's profit.

2.03×
Net margin

Net margin

How much of every rupee of sales survives to profit.

How it's worked out

Net profit after tax divided by sales, from the annual filing.

How to read it

Compare it only within an industry — a supermarket at 3% can be healthier than a manufacturer at 10%. The direction matters more than the level.

10.6%
Margin, 3-year change

Margin, 3-year change

Whether the business is getting more or less profitable.

How it's worked out

The latest net margin minus the one three years earlier, in percentage points.

How to read it

A widening margin on flat sales is a company with pricing power. A shrinking one is usually costs, competition, or both.

+4.5 pts
EPS growth, 3-year

EPS growth, 3-year

How fast profit per share has compounded.

How it's worked out

The annual rate that turns the earnings per share of three years ago into today's.

How to read it

Blank if the company was losing money three years ago — a move from a loss to a profit has no meaningful growth rate, and printing one would be arithmetic pretending to be insight.

+38.4% a year
Sales growth, 3-year

Sales growth, 3-year

How fast revenue has compounded.

How it's worked out

The annual rate that turns the sales of three years ago into today's.

How to read it

Read it next to EPS growth. Sales rising faster than profit means the growth is being bought with margin.

+15.3% a year

It paid out 49% of earnings and kept the rest.

Can you actually trade it

Median traded per session

Traded per session

The rupees that change hands on a typical day.

How it's worked out

The median of price times volume over the last 60 sessions — the median, so one block trade cannot make a dead stock look busy.

How to read it

This is the number that decides whether the quoted price is a price you can actually get.

Rs 6.7M
Sessions to trade Rs 1M

Sessions to trade Rs 1M

How long it would take to trade into or out of a Rs 1,000,000 position.

How it's worked out

Rs 1,000,000 divided by the median rupees traded a session.

How to read it

Under 0.01 and your order is a rounding error. Above 1 and you are the day's volume — expect to move the price against yourself getting out.

0.15
Untraded sessions, last 60

Untraded sessions

Days in the last 60 when literally nothing traded.

How it's worked out

A count of sessions with zero volume.

How to read it

Any number above zero means there are days you could not have sold at any price. On PSX this is common well outside the KSE-100.

0
Daily volume vs free float

Daily volume vs free float

What share of the tradable stock changes hands on a normal day.

How it's worked out

Average daily volume divided by the free float — the shares not locked up by sponsors.

How to read it

A company can be huge and still barely trade if the family owns 90% of it. This separates size from liquidity.

0.07%
Price impact per Rs 1M traded

Price impact per Rs 1M

How much a Rs 1,000,000 order moves the price on a typical day.

How it's worked out

We take the size of the price move on each day and divide it by the money traded that day, then scale it to a Rs 1,000,000 order. We use the middle value over the last year. Traders call this the Amihud ratio. It is shown in basis points: 100 basis points is 1%, so 0.07 basis points is 0.0007%.

How to read it

A small number means an order of this size barely moves the price. A large number means the price moves a lot when someone buys or sells this much.

7 bps
Implied bid-ask spread

Implied bid-ask spread

The hidden cost of a round trip, estimated from the price series.

How it's worked out

Roll's estimator: prices bounce between bid and ask, and the size of that bounce implies the spread.

How to read it

It is the toll you pay to enter and leave, before any brokerage. Blank when the price is trending rather than bouncing, because then the model does not apply and we would rather say nothing.

1.12%
Float turned over, one year

Float turned over, one year

How many times the tradable stock changed hands in a year.

How it's worked out

A year's volume divided by the free float. Exchanges publish this about themselves; this is the same measure for one company.

How to read it

100% means the entire float turned over once. Single digits mean a register that never moves, whatever the market cap says.

33%
Sessions with a trade, one year

Sessions with a trade

How often it trades at all.

How it's worked out

The share of the last 250 sessions with any volume.

How to read it

Anything below 100% means there were days with no market. Below 90% is more than 25 such days in the last 250 — on each of those days no trade happened at any price, so an order placed that day did not execute.

100%

Liquidity is comfortable: a Rs 1,000,000 order is about 15% of a normal session's turnover.

A Rs 1,000,000 ticket nudges the price — about 7 basis points on the median session.

What the risk paid

Total return, one year

Total return, one year

What a holder actually made, dividends included.

How it's worked out

The price move over twelve months plus every cash dividend paid in that window, counted as received on its ex-date.

How to read it

Every other PSX site quotes the price move alone. On a market yielding what this one does, that understates what holders made by a third or more.

-2.2%
— from the price
-5.9%
— from dividends

— from dividends

The part of the year's return that arrived as cash.

How it's worked out

Dividends per share over the year divided by the price twelve months ago.

How to read it

The half of the return a price chart cannot show you. For many PSX names it is most of it.

+3.7%
Return per unit of risk

Return per unit of risk

How much you were paid for how rough the ride was.

How it's worked out

The one-year return divided by the annualised volatility of the daily moves.

How to read it

Two stocks up 20% are not the same if one did it calmly and the other halved on the way. Deliberately not a Sharpe ratio: quoting a risk-free rate for Pakistan means picking a T-bill tenor and pretending that was your alternative.

-0.20
Alpha vs KSE-100, one year

Alpha vs KSE-100

The part of the year's return the market does not explain.

How it's worked out

The stock's return minus its beta times the index's return.

How to read it

A high-beta name rising in a rising market has done nothing clever. This strips that out and leaves what was actually the company's doing.

-7.8 pts
Caught of the market's up moves

Caught of the market's up moves

How much of the market's good days this stock catches.

How it's worked out

The stock's total return across the index's up days, divided by the index's own.

How to read it

Above 100 means it rises more than the market does. Read it with down capture — the pair is the whole picture, either half alone flatters.

70%
Caught of its down moves

Caught of its down moves

How much of the market's bad days this stock catches.

How it's worked out

The stock's total return across the index's down days, divided by the index's own.

How to read it

Below 100 means it falls less than the market. Above 100 means it falls further than the market does on the market's bad days, which a headline return usually hides.

78%
Worst day in twenty

Worst day in twenty

The fall to expect on a bad day.

How it's worked out

The fifth-percentile daily return over the last year — the actual distribution, not a bell curve.

How to read it

One session in twenty is at least this bad. It is a normal day at the office, not a crash, and the crash is worse than this by definition.

−2.9%
Below its 52-week high

Below its 52-week high

How far under its best price of the year it sits now.

How it's worked out

The 52-week high minus today's price, as a percentage of that high.

How to read it

Different from the biggest drawdown, which is the worst it ever got. This is the hole still to climb out of.

20.5% · 214 sessions

It has fallen with the index more than it has risen with it.

Brokers’ price targets

Brokers’ 12-month price targets for ABOT, not SuperX’s

Collected from sell-side research notes. The figures here are the brokers’.

No broker covers ABOT in our records. Brokers cover 49 PSX companies and rate 47 of them buy.

Computed value range

Where the middle half of Pharmaceuticals’s price-to-earnings ratios would put the price: Rs 900.16 to Rs 1,513.28. 12 companies, 2 left out (a loss, no ratio, or a ratio over 100). Earnings per share Rs 81.37 for the period to 31 Dec 2025, from company accounts. A method, not advice.

The price of Rs 1,013.28 on 20 Nov 2026 is inside this range. The middle of the range is Rs 1,014.28.

Computed value range

Source: PSX ratios, filed accounts.

The band is the range, the tick is its middle and the arrow is the price. Source: the exchange’s price-to-earnings ratios and filed accounts.

SuperX’s own method, worked out from the exchange’s ratios. It is not a broker’s target and not advice.

03Grades and checks5 checks

Grades, A to F

As of 20 Nov 2026. Each grade ranks ABOT among 408 traded companies (at least Rs 10 m traded on 18 of the last 20 sessions), across the whole market and not only its sector. A: the top 20%. B: 60 to 80. C: 40 to 60. D: 20 to 40. F: the bottom 20%. The figures in a grade count equally.

Grade ranks, 0 to 100

Scale 0 to 100: the share of graded companies this one is ahead of.
MethodThe letter is the grade. The sector median is over 14 companies. The inputs are listed below.
Price against earnings, book value and dividendD

ahead of 36.2% of graded companies · from 3 of 3 figures

  • earnings over price: 9.36%, ahead of 43% of companies
  • book value over price: 31.85%, ahead of 16% of companies
  • dividend yield: 3.95%, ahead of 74% of companies
Growth in sales and earningsB

ahead of 77.0% of graded companies · from 2 of 2 figures

  • sales growth, 3 years: 15.25%, ahead of 70% of companies
  • earnings per share growth, 3 years: 38.41%, ahead of 78% of companies
Profit margin and return on equityB

ahead of 74.6% of graded companies · from 2 of 2 figures

  • net profit as a share of sales: 10.57%, ahead of 64% of companies
  • profit over shareholders’ equity: 25.19%, ahead of 86% of companies
Price change over 90 days, 182 days and 1 yearB

ahead of 74.1% of graded companies · from 3 of 3 figures

  • return, 90 days: 11.34%, ahead of 81% of companies
  • return, 182 days: 16.32%, ahead of 70% of companies
  • return, 1 year: -5.91%, ahead of 50% of companies

Each letter shows where the company’s own figures stand among the traded companies on that date. Not advice and not a forecast.

What's good about ABOT

As of 20 Nov 2026

Each line names the test it passed, in the small print under it. Nothing here is scored or ranked.

One side only: None of these checks found a point against ABOT. That does not mean there is none.

In its favour

  • Cheaper on earnings than 81% of pharmaceuticals.

    price per rupee earned in the cheapest quarter of its sector

  • The multiple is covered by growth — a PEG of 0.28.

    PEG below 1 on three-year earnings growth

  • The dividend is covered 2.0 times by earnings.

    Earnings at least twice the dividend

  • Earnings per share compounded 38% a year over three years.

    Three-year EPS growth of 15% or more

  • Net margin is 4.5 points wider than three years ago.

    Margin up 2 points or more over three years

Not advice, and not a score. Each line describes a figure on this page.

04ResultsBy year and by quarter
Sales, profit and earnings per share, by year

What are ABOT’s sales, profit and earnings per share?

Results, by period end

Earnings per share by financial year, Rs, with the change on the year before

Earnings per share, Rs, by year to the month shown; in brackets, the change on the year before (none where no year before is filed).

Sales by financial year, Rs billion

Sales, Rs billion.

Profit margins by financial year

Share of sales, by year.
PeriodEarnings per share (Rs)SalesNet profit as a share of salesChange in earnings per share on the year before
Year to 31 Dec 202581.37Rs 75.4 bn10.57%+52.2%
Year to 31 Dec 202453.46Rs 68.2 bn7.68%+1,902.2%
Year to 31 Dec 20232.67Rs 55.5 bn0.47%-91.3%
Year to 31 Dec 202230.69Rs 49.3 bn6.10%—

Sales and profit after tax by quarter, Rs billion

Sales and profit after tax by quarter, Rs bn.
MethodA blank is a quarter not filed separately. The fourth quarter is filed only inside the annual accounts.
QuarterEarnings per share (Rs)SalesProfit after taxChange on the same quarter a year before
Quarter to 30 Sep 202625.99Rs 20.6 bnRs 2.5 bn+39.6%
Quarter to 30 Jun 202622.47Rs 20.3 bnRs 2.2 bn+13.2%
Quarter to 31 Mar 202619.82Rs 17.7 bnRs 1.9 bn—
Quarter to 30 Sep 202518.62Rs 19.8 bnRs 1.8 bn—
Quarter to 30 Jun 202519.85Rs 19.1 bnRs 1.9 bn—

Company accounts as filed. Earnings per share are on today’s share count where a split or bonus issue came later. Years to 31 December. 4 of the last 5 years and 5 of the last 8 quarters.

Next results

Full-year results, to 31 Dec 2026: expected between 2 Feb 2027 and 16 Mar 2027.

A projection, not an announced date. An estimate from the dates of the last 6 filings.

Annual figures from the accounts filed with PSX. Amounts in rupees; earnings per share (EPS) in rupees a share.

Statements in SuperX Apex

FY (December) 2025202420232022
Sales Rs 75.4BRs 68.2BRs 55.5BRs 49.3B
Profit after Taxation Rs 8BRs 5.2BRs 262MRs 3B
EPS Rs 81.37Rs 53.46Rs 2.67Rs 30.69
EPS Growth +52.2%+1902.3%−91.3%−49.6%
Gross Profit Margin 35.1%28.9%21.4%29.5%
Net Profit Margin 10.6%7.7%0.5%6.1%
05AccountsCash, debt and the balance sheet

Where the cash came from and went

Profit after taxRs 8.0 bn
Operating cash flowRs 10.7 bn
Capital spending−Rs 3.3 bn
Free cashworked out: operating cash flow less capital spendingRs 7.4 bn
Dividends paid−Rs 971.6 m
Change in cashRs 7.2 bn
Cash at the start of the yearRs 6.2 bn
Cash at the end of the yearRs 13.3 bn

Accounts, year to 31 Dec 2025 · filed annual report, page 94The report does not say whether these are group accounts or the company’s own.

Ratios from the filed accounts

Cash earned for each rupee of profitoperating cash flow over profit after taxRs 1.35
Free cash as a share of sales9.9%
Change in earnings per share on the year before+52.2%
Price per rupee earned, our owncompany accounts, twelve months to 31 Dec 202512.45

The other rows: accounts, year to 31 Dec 2025 · filed annual report, page 94The report does not say whether these are group accounts or the company’s own.

Yes-or-no tests on the accounts

Year to 31 Dec 2025 against year to 31 Dec 2024.

Met and not met

A filled dot is a test the accounts meet; a ring is a test they do not meet.
Profit after tax above zerothis year Rs 8.0 bnmet
Operating cash flow above zerothis year Rs 10.7 bnmet
Operating cash flow above profit after taxthis year Rs 10.7 bn, profit after tax Rs 8.0 bnmet
Gross profit as a share of sales rosethis year 35.1%, year before 29.0%met

4 of the 9 tests are shown. The other tests cannot be worked out from the accounts shown here, so no total is given.

Accounts, year to 31 Dec 2025 · filed annual report, page 94The report does not say whether these are group accounts or the company’s own.

Balance sheet and returns

Abbott Laboratories (Pakistan) balance sheet and returns

Return on equity, book value, gearing and margins for Abbott Laboratories (Pakistan), from the company’s own audited annual report. Figures for the year ended 31 Dec 2025, 11 months old.

Return on equity

Return on equity

What the company earned on the shareholders' own money.

How it's worked out

Profit after tax divided by total equity, both from the balance sheet in the company's latest annual report. PSX publishes no balance sheet, so this is read out of the filing itself.

How to read it

The headline test of whether management is any good. Above about 20% is high for PSX; below the rate a bank deposit pays means the business earns less than doing nothing. Blank on negative equity, where the number flatters instead of informing.

25.19%
Return on assets

Return on assets

Earnings against everything the company controls, not just what shareholders put in.

How it's worked out

Profit after tax divided by total assets, from the annual report's balance sheet.

How to read it

Read it beside return on equity. A wide gap between the two is borrowed money doing the work — on a bank or a leasing company, that gap is the whole story.

17.02%
Book value / share

Book value per share

The accounting value of one share, in rupees.

How it's worked out

Total equity divided by shares outstanding — what each share would be worth if the company sold everything at balance-sheet value and paid off every debt.

How to read it

The floor under a share price, loosely. It ignores brands, people and future profits, so a good business trades well above it and a broken one below.

Rs 323.03
Price to book

Price to book

What the market charges for each rupee of net assets.

How it's worked out

Share price divided by book value per share.

How to read it

Under 1 means the market values the whole company at less than the net assets on its own balance sheet. On PSX that is common and is sometimes a bargain and sometimes a warning — check why.

3.14×
Current ratio

Current ratio

Can it pay the bills due inside a year?

How it's worked out

Current assets divided by current liabilities, from the annual report.

How to read it

Under 1 means more falls due within a year than the company expects to collect within one. Not fatal on its own — but it is the first place to look when a company is in trouble.

2.32×
Liabilities to equity

Liabilities to equity

How much is owed against how much is owned outright.

How it's worked out

Total liabilities divided by total equity. The broad measure — all liabilities, not only interest-bearing borrowings — because that is what the published tables reliably carry.

How to read it

Leverage magnifies both directions. High gearing is normal for banks and leasing, alarming for a manufacturer in a high-rate year like Pakistan has had.

0.48×
Funded by shareholders

Funded by shareholders

The share of the balance sheet shareholders actually paid for.

How it's worked out

Total equity as a percentage of total assets — the plain-English complement of leverage.

How to read it

The higher it is, the less the company depends on lenders staying friendly. At Pakistani interest rates that dependence has cost a great deal.

68%
Gross margin

Gross margin

What's left of each sales rupee after the cost of making the thing.

How it's worked out

Gross profit as a percentage of sales, from the annual report.

How to read it

Pricing power in one number. A margin that holds while the rupee falls means the company can pass costs on; one that shrinks means it cannot.

35.08%
Operating margin

Operating margin

What's left of each sales rupee after running the business.

How it's worked out

Operating profit as a percentage of sales — after overheads, before interest and tax.

How to read it

The cleanest view of the business itself, stripped of how it is financed and taxed.

18.00%
Effective tax rate

Effective tax rate

The share of pre-tax profit that actually went to the FBR.

How it's worked out

Taxation divided by profit before tax, from the annual report. Blank on a pre-tax loss, where the ratio inverts and means nothing.

How to read it

Pakistan's headline corporate rate plus super tax means many companies pay far more than 29%. A rate well above peers is a real drag on what reaches shareholders.

41%
Year ended Total assets Equity Revenue Profit Return on equity
31 Dec 2025accounts not labelled Rs 46.8B Rs 31.6B Rs 75.4B Rs 8B 25.2%
31 Dec 2024accounts not labelled Rs 37.7B Rs 23.7B Rs 68.2B Rs 5.2B 22.1%
31 Dec 2023accounts not labelled Rs 36.7B Rs 18.2B Rs 55.5B Rs 262M 1.4%
31 Dec 2022accounts not labelled Rs 33.9B Rs 17.1B Rs 49.3B Rs 3B 17.6%
31 Dec 2021accounts not labelled Rs 28.6B Rs 17.4B Rs 42.6B Rs 6B 34.4%
31 Dec 2020accounts not labelled Rs 24.9B Rs 15.6B Rs 35.3B Rs 4.5B 29.1%

Source: Abbott Laboratories (Pakistan)’s annual report, page 78. Every figure above can be checked against it.

06DividendsRs 40.00 a share, 12 months
Every payout

What dividends has ABOT paid?

PSX quotes payouts as a % of the Rs 10 face value — 25% = Rs 2.50 per share. Unconfirmed ex-dates are marked “expected”.

Full dividend history

Payouts in SuperX Apex

Dividends, by financial year

Cash dividends, counted in the financial year of the ex-dividend date. Twelve months from 20 Nov 2025: Rs 40.00 a share.

Dividends paid a share by financial year, with the yield at each year end

Cash dividends, counted in the financial year of the ex-dividend date.
MethodBars: paid a share on today's share basis, after splits and bonus issues. Yield: the year's dividends over the last close on or before the year end. A year with no yield shows no point. * The year in progress. Source: PSX payout notices and closes.
Financial yearPaid a sharePayoutsYield at year end
Year to 31 Dec 2026 (year in progress)Rs 40.001—
Year to 31 Dec 2025Rs 10.0010.95%
Year to 31 Dec 2022Rs 35.0027.55%

Source: PSX payout notices.

ABOT dividends and corporate actions
Type % of face Per share Ex-date Book closure Qualify by
Cash dividend 400% Rs 40.00 22 Apr 2026 23 Apr 2026 – 30 Apr 2026 21 Apr 2026
Cash dividend 100% Rs 10.00 14 Apr 2025 16 Apr 2025 – 23 Apr 2025 11 Apr 2025
07Peers6 companies
Peers table

Other Pharmaceuticals stocks on PSX

Other companies in the same PSX sector, including its largest.

Against the largest companies in its sector

Price per rupee earned

Dividend yield, payers only

Net profit as a share of sales

Price change over 1 year

Market value, Rs billion

Market value, Rs billion, and its share of the 6 companies shown.

The company and the largest 5 others in its sector by market value, as of 20 Nov 2026. Sources: PSX prices and filed accounts.

ABOT sector peers
Symbol Company Price Chg % Mkt cap Price/earnings
AGP AGP Limited 151.65 +0.44% Rs 42.5B 23.7×
BFBIO BF Biosciences Limited 137.22 −0.74% Rs 12.1B 18.4×
CPHL Citi Pharma Ltd. 62.18 −0.27% Rs 14.2B 17.5×
GLAXO GlaxoSmithKline Pakistan Limited 332.02 −0.92% Rs 106B 9.6×
HALEON Haleon Pakistan Limited 687.73 0.00% Rs 80.5B 12.3×
HINOON Highnoon Laboratories Limited 976.84 +1.74% Rs 51.8B 12.6×

6 of 6 companies shown have a price-to-earnings ratio in Pharmaceuticals; a blank cell means a loss or no ratio. Each ratio is the one printed on that company’s own page, to 20 Nov 2026.

All Pharmaceuticals stocks on PSX

08Price position42% of the 52-week range

Where the price stands

Closing price over one year

One close every two weeks to 20 Nov 2026, closes adjusted for splits and bonus issues.
MethodThe 52-week low 821.00 and high 1,274.00 are intraday highs and lows, set 13 Mar 2026 and 8 Jan 2026. Source: PSX closes.

Closing price over the last 20 sessions

Last 20 sessions, 23 Oct 2026 to 20 Nov 2026, closes adjusted for splits and bonus issues. Source: PSX closes.

Levels where the price turned most often in the last 12 months, one below and one above the close on 20 Nov 2026. A turn is a daily high or low that is the highest or lowest of the 5 sessions before it and the 5 after it; turns close together count as one level. Each line runs from its first turn to its last and stops there. Prices from 21 Nov 2025 to 20 Nov 2026, 248 sessions, adjusted for splits and bonus issues. Source: PSX daily prices.

  • Rs 903.45, below the close on 20 Nov 2026: 5 turns, the first on 1 Jun 2026 and the last on 15 Oct 2026.
  • Rs 1,027.30, above the close on 20 Nov 2026: 2 turns, the first on 2 Jul 2026 and the last on 6 Nov 2026.

Dated events on the one-year chart, 20 Nov 2025 to 20 Nov 2026, newest first: R results filed, D ex-dividend, B bonus issue, S split, T dealing by a director or major owner. Marked: dividend, bonus and split dates in the window, the latest results filing and the latest dealings. A number marks that many events too close together to draw apart. Sources: the company’s notices to PSX and the exchange’s payout records.

  • R 27 Oct 2026 · Results filed: Nine-month results, to 30 Sep 2026
  • D 22 Apr 2026 · Ex-dividend: Rs 40.00 a share

Place in the 52-week range

0% is the low and 100% the high of the last 52 weeks, as of 20 Nov 2026. Other companies: the largest in the same sector.
Place in the 52-week range
42.4% of the way from the low to the highintraday highs and lows, as of 20 Nov 2026

Reading of the last 14 days, weeks and months

Scale 0 to 100. Below 30 and above 70 mark the two outer bands. 14 completed days, weeks and months. Source: PSX closes.
Reading of the last 14 sessions
68.9 on a scale of 0 to 100, between 30 and 70session of 20 Nov 2026; below 30 and above 70 mark the two outer bands
Week reading, 14 weeks
58.4 on a scale of 0 to 100week to 20 Nov 2026; close Rs 1,013.28, above the average of the last 10 weekly closes, Rs 953.76
Month reading, 14 months
53.9 on a scale of 0 to 100month to 30 Oct 2026; close Rs 966.69, level with the average of the last 10 monthly closes, Rs 957.44; level means within 1% of the average

Trend strength, 14 sessions

14 daily sessions, scale 0 to 100. Source: PSX highs, lows and closes.
Trend strength, 14 sessions
30.4 on a scale of 0 to 100over 14 daily sessions
Volume
7,648, 0.6 times the average of the 30 sessions before it, 13,634Average of the 30 sessions before the last.

PSX daily closes, as of 20 Nov 2026.

Trend and technical readings

Trend read

Leaning Up

Since 2 Nov 2026 · daily closes to 20 Nov 2026

  • •Above the 50-day average
  • •Up 11.3% over 3 months
  • •Up 7.6% over 1 month

A description of the price series — moving averages, momentum, the 52-week position — held for three closes before it changes. It is a label, not advice. How it works

Buying vs selling, 14 sessions

Buying vs selling, 14 sessions

Whether recent buying or selling has run hot.

How it's worked out

Fourteen sessions of gains weighed against losses, on a 0–100 scale.

How to read it

Above 70 is called overbought and below 30 oversold. A share that keeps rising can sit above 70 for months, so this describes what the price has done; it does not forecast a turn.

69
neutral band
vs 50-day avg
+6.9%
SMA Rs 947.46
vs 200-day avg
+6.4%
SMA Rs 952.39
Beta vs KSE-100

Beta

How hard it swings when the market swings.

How it's worked out

The slope of this stock's daily returns against the KSE-100's, over a year of sessions.

How to read it

1.0 moves with the market, 1.5 exaggerates it by half, below 1 is steadier. It says nothing about direction, only about size.

0.78
correlation 0.70 · 1Y
Volatility

Volatility, 30-day

How jumpy it has been lately, stated per year.

How it's worked out

The standard deviation of the last 30 days of returns, annualised.

How to read it

30% means a typical year's swing of about thirty percent either way. Rising volatility often arrives before news does.

20%
30d · 19% 90d, annualised
Max drawdown · 1Y

Biggest drawdown

The worst peak-to-trough fall of the last year.

How it's worked out

The largest drop from any high to any subsequent low over 250 sessions.

How to read it

The number that tells you whether you could have held it. Most people discover their real risk tolerance somewhere inside this figure.

−33.5%
Volume vs 20-day avg

Volume vs normal

How busy today was against a typical day.

How it's worked out

The latest session's volume divided by the twenty-day average.

How to read it

Above 2 means something happened — an announcement, a block, a rumour. Check the news before reading anything into the price.

0.49×
20-session average 15,853
52-week signal

Position in 52-week range

Where today's price sits between the year's low and high.

How it's worked out

Zero at the 52-week low, 100 at the high.

How to read it

Near 100 is strength or froth; near 0 is a bargain or a falling knife. The number tells you where you are, never which of the two.

Inside range

Figures as of 20 Nov 2026, from daily closes.

09OwnersWho owns the shares

Who holds the shares

Free float
21.6% of sharesas of 11 Nov 2026
Held in the central depository, other than by the government
21.6%as of 30 Nov 2025

Source: SuperX ownership data · free float as of 11 Nov 2026, custody file of 30 Nov 2025.

Owners as the annual report lists them

97,900,302 shares in all, as of 31 Dec 2025.

WhoOwnersSharesShare of all shares
Directors and their families622,4510.02%
Associated companies377,189,06678.84%
NIT and ICP29800.00%
Banks and financial institutions83,047,4603.11%
Mutual funds and modarabas404,138,5894.23%
Insurance and takaful companies131,073,2251.10%
General public, local3,7487,994,7868.17%
Others1684,433,7454.53%

Source: the pattern of shareholding in the annual report, as of 31 Dec 2025 · annual report, page 160

About the company

About Abbott Laboratories (Pakistan) Limited

Abbott Laboratories (Pakistan) Limited is a public limited company incorporated in Pakistan on July 02, 1948. The Company is principally engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products.

Key people

  • Syed Anis Ahmed · CEO
  • Ehsan A. Malik · Chairperson
  • Muhammad Usama Jamil · Company Secretary
Head office
Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi, Pakistan
Auditor
EY Ford Rhodes, Chartered Accountants
Share registrar
FAMCO Share Registration Services (Pvt) Limited, 8-F, Next to Hotel Faran, Nursery Block 6, P.E.C.H.S, Shahrah-e-Faisal,Karachi
Fiscal year end
December
10Dated record47 dated events

What matters now for ABOT

Three dates that matter, as of 20 Nov 2026.

  • Last ex-dividend

    22 Apr 2026

    Rs 40.00 a share

    the first day a buyer gets no dividend. 212 days before 20 Nov 2026.

  • Next results

    2 Feb 2027

    Full-year results expected between 2 Feb 2027 and 16 Mar 2027

    projected — An estimate from this company’s own past filing dates. Not a date the company gave. 74 days after 20 Nov 2026.

  • Last large move

    5 Nov 2026

    +3.18%

    ABOT closed up 3.2% at Rs 1,000.30. This was a sector day. 13 of 15 PHARMACEUTICALS stocks rose. The typical one rose 2.6%. 41,385 shares traded, 3.0 times a normal day. ABOT filed nothing that moves a price, that session or the day before.

The dated record

ABOT’s dated record

The exchange’s own record and ours: ex-dividends, book closures, results, every session move of 3% or more with the reason written out, the notices that move a price, and the news about Abbott Laboratories (Pakistan). Dates that have not happened are kept apart from dates that have, and each one says whether it was announced or projected.

Ahead · 1

These dates are after 20 Nov 2026. None of them has happened. A row marked  projected  is an estimate from the company’s past filing dates; a row marked  announced  is a date on the exchange’s record.

  • 2 Feb 2027 Results Full-year results expected between 2 Feb 2027 and 16 Mar 2027 projected — An estimate from this company’s own past filing dates. Not a date the company gave.

The last 90 days · 7

  • 5 Nov 2026

    • Move +3.18% ABOT closed up 3.2% at Rs 1,000.30. This was a sector day. 13 of 15 PHARMACEUTICALS stocks rose. The typical one rose 2.6%. 41,385 shares traded, 3.0 times a normal day. ABOT filed nothing that moves a price, that session or the day before.
  • 27 Oct 2026

    • Notice Financial results Financial Results for the Quarter Ended September 30, 2026
    • Results Nine-month results, to 30 Sep 2026
    • Move +4.65% ABOT closed up 4.7% at Rs 967.16. Its sector's typical stock rose 0.4%; the KSE-100 rose 0.9%. So this was ABOT's own move. 66,286 shares traded, 7.8 times a normal day.

    same day, order not known

  • 20 Oct 2026

    • Notice Board meeting Board Meeting
  • 31 Aug 2026

    • Move -3.23% ABOT closed down 3.2% at Rs 940.26. Its sector's typical stock fell 0.6%; the KSE-100 fell 0.4%. So this was ABOT's own move. 109,610 shares traded, 2.7 times a normal day. ABOT filed nothing that moves a price, that session or the day before.
  • 28 Aug 2026

    • Notice Financial results Financial Results for the Half Year Ended June 30 2026

Earlier · 39

Notice 17 notices, 26 Aug 2024 to 20 Aug 2026 open
  • 20 Aug 2026 Board meeting Board Meeting
  • 27 Apr 2026 Financial results Financial Results for the Quarter Ended March 31, 2026
  • 20 Apr 2026 Board meeting Board Meeting
  • 16 Mar 2026 Financial results Financial Results for the Year Ended December 31, 2025
  • 9 Mar 2026 Board meeting Board Meeting
  • 29 Oct 2025 Financial results Financial Results for the Quarter Ended September 30, 2025
  • 22 Oct 2025 Board meeting Board Meeting
  • 28 Aug 2025 Financial results Financial Results for the Quarter Ended June 30, 2025
  • 20 Aug 2025 Board meeting Board Meeting
  • 28 Apr 2025 Financial results Financial Results for the Quarter Ended March 31, 2025
  • 21 Apr 2025 Board meeting Board Meeting
  • 25 Feb 2025 Financial results Additional Information to Financial Results for the Year Ended 31st December 2024
  • 20 Feb 2025 Financial results Financial Results for the Year Ended December 31st, 2024
  • 13 Feb 2025 Board meeting Board Meeting
  • 25 Oct 2024 Financial results Financial Results for the Quarter Ended September 30, 2024
  • 18 Oct 2024 Board meeting Board Meeting
  • 26 Aug 2024 Financial results Financial Results for thr Quarter Ended June 30 2024
Move 17 session moves, 8 Jan 2026 to 16 Jul 2026 open
  • 16 Jul 2026 +4.29% ABOT closed up 4.3% at Rs 970.80. Its sector rose too: 11 of 15 stocks, the typical one by 1.4%. ABOT beat that by 2.9 points. 71,748 shares traded, 1.3 times a normal day. ABOT filed nothing that moves a price, that session or the day before.
  • 8 Jul 2026 -3.02% ABOT closed down 3.0% at Rs 967.08. This was a sector day. 14 of 14 PHARMACEUTICALS stocks fell. The typical one fell 3.0%. It opened flat and fell through the day. 44,352 shares traded, 0.8 times a normal day.
  • 15 Jun 2026 +3.98% ABOT closed up 4.0% at Rs 924.24. This was a sector day. 13 of 14 PHARMACEUTICALS stocks rose. The typical one rose 3.8%. 61,357 shares traded, 1.2 times a normal day. ABOT filed nothing that moves a price, that session or the day before.
  • 8 Apr 2026 +10% Up 10.0% on 11.9× the usual volume, gapping 10.0% at the open. The pharmaceuticals sector moved the same way, median +10.0% (15 of 15 names up). The KSE-100 moved +9.3% the same day. Foreign investors were net sellers of Rs 1,793M across the market.
  • 1 Apr 2026 +3.72% Up 3.7% on 0.8× the usual volume. The pharmaceuticals sector moved the same way, median +4.2% (13 of 14 names up). The KSE-100 moved +4.6% the same day.
  • 30 Mar 2026 -3.02% Down 3.0% on 0.7× the usual volume. The pharmaceuticals sector moved the same way, median -4.0% (14 of 14 names down). The KSE-100 moved -3.2% the same day.
  • 16 Mar 2026 +4.97% Up 5.0% on 1.1× the usual volume. Against the pharmaceuticals sector, which moved -2.4%. Financial results were announced within the last two sessions.
  • 10 Mar 2026 +4.88% Up 4.9% on 2.9× the usual volume, gapping 3.5% at the open. The pharmaceuticals sector moved the same way, median +7.9% (14 of 15 names up). The KSE-100 moved +6.6% the same day. A board meeting was notified within the last two sessions.
  • 9 Mar 2026 -8.4% Down 8.4% on 4.3× the usual volume, gapping 6.8% at the open. The pharmaceuticals sector moved the same way, median -9.6% (14 of 14 names down). The KSE-100 moved -7.0% the same day. A board meeting was notified within the last two sessions.
  • 6 Mar 2026 -3.38% Down 3.4% on 0.7× the usual volume. The pharmaceuticals sector moved the same way, median -3.1% (15 of 15 names down). The KSE-100 moved -2.3% the same day.
  • 5 Mar 2026 -3.5% Down 3.5% on 4.5× the usual volume. Foreign investors were net sellers of Rs 1,378M across the market.
  • 3 Mar 2026 +5.55% Up 5.5% on 2.1× the usual volume, gapping 4.7% at the open. The KSE-100 moved +3.4% the same day. Foreign investors were net sellers of Rs 1,762M across the market.
  • 2 Mar 2026 -8.15% Down 8.2% on 0.5× the usual volume, gapping 5.3% at the open. The pharmaceuticals sector moved the same way, median -10.0% (14 of 14 names down). The KSE-100 moved -9.6% the same day. Foreign investors were net sellers of Rs 1,254M across the market.
  • 24 Feb 2026 -3.33% Down 3.3% on 2.5× the usual volume.
  • 23 Feb 2026 -6.03% Down 6.0% on 1.1× the usual volume. The pharmaceuticals sector moved the same way, median -3.6% (15 of 15 names down). The KSE-100 moved -3.2% the same day.
  • 9 Feb 2026 +3.33% Up 3.3% on 0.6× the usual volume. The pharmaceuticals sector moved the same way, median +1.2% (10 of 15 names up). Foreign investors were net sellers of Rs 1,022M across the market.
  • 8 Jan 2026 +3.99% Up 4.0% on 2.0× the usual volume. Foreign investors were net sellers of Rs 1,043M across the market.
Ex-dividend 5 ex-dividends, 8 Sep 2021 to 22 Apr 2026 open
  • 22 Apr 2026 Rs 40.00 a share
  • 14 Apr 2025 Rs 10.00 a share
  • 8 Sep 2022 Rs 15.00 a share
  • 15 Apr 2022 Rs 20.00 a share
  • 8 Sep 2021 Rs 20.00 a share

Showing the most recent session moves and notices. Every ex-dividend, book closure, results filing and ticker change is listed.

Announcements on PSX

What has Abbott Laboratories (Pakistan) announced on PSX?

The latest 5 notices Abbott Laboratories (Pakistan) filed with the exchange, newest first. The title is the exchange’s own text, as filed. The PDF opens at PSX.

  • 30 Oct 2026 · Report sent to shareholders Transmission of Quarterly Reports for the Period Ended September 30, 2026 PDF on PSX
  • 27 Oct 2026 · Financial results Financial Results for the Quarter Ended September 30, 2026 PDF on PSX
  • 20 Oct 2026 · Board meeting Board Meeting PDF on PSX
  • 28 Aug 2026 · Report sent to shareholders Transmission of Quarterly Financial Statements for the Period Ended June 30, 2026 PDF on PSX
  • 28 Aug 2026 · Financial results Financial Results for the Half Year Ended June 30 2026 PDF on PSX

From the company’s announcements on the Pakistan Stock Exchange (dps.psx.com.pk), read 21 Nov 2026.

Dates and events on this page are read as of 20 Nov 2026.

11QuestionsQuick answers

ABOT share price: quick answers

What is the Abbott Laboratories (Pakistan) (ABOT) share price?

As of 20 Nov 2026, the Abbott Laboratories (Pakistan) (ABOT) share price is Rs 1,013.28 (+0.42% on the day). Over the last year it has moved −5.91%.

What was ABOT's last dividend?

Its last cash dividend was Rs 40.00 a share, ex-date 22 Apr 2026.

What is ABOT's dividend yield?

As of 20 Nov 2026, Abbott Laboratories (Pakistan) Limited (ABOT) has a trailing dividend yield of 3.95% at a share price of Rs 1,013.28. Cash dividends declared over the last 12 months total Rs 40.00 per share.

How much does ABOT cost for each rupee it earns?

At Rs 1,013.28 a share on 20 Nov 2026, each rupee ABOT earned over the last twelve months costs Rs 10.68. That is a trailing price-to-earnings ratio of 10.68×. Its market capitalisation is about Rs 99.2B.

Is ABOT Shariah compliant?

Yes. PSX lists Abbott Laboratories (Pakistan) Limited (ABOT) as Shariah-compliant as of 20 Nov 2026 and is included in the KMI All-Share Islamic index. Screening status can change at each review, so confirm with your Shariah advisor before investing.

Is ABOT trending up or down?

SuperX's trend read for ABOT is Leaning Up since 2 Nov 2026: see the reasons on this page. Above the 50-day average; Up 11.3% over 3 months; Up 7.6% over 1 month. The read describes the closes through 20 Nov 2026; it is not a recommendation.

What does ABOT cost against what it earns?

ABOT shows an earnings yield of 9.36%, a payout ratio of 49%, a net margin of 10.6%. Its price-to-earnings multiple is lower than 81% of companies in the same PSX sector with reported earnings. Whether that price is low or high depends on why the market sets it there, which no ratio answers. A Rs 1,000,000 order is about 15% of a normal session, judged on the median value traded over the last 60 sessions.

What is the total return on ABOT including dividends?

ABOT returned -2.2% over the last year counting the cash dividends paid, against a price move of -5.9% — a gap of 3.7 percentage points that a price chart alone hides. Dividends are counted as received on their ex-date, not reinvested. Figures to 20 Nov 2026.

How liquid is ABOT?

On SuperX's reading of the last 60 sessions, a Rs 1,000,000 order moves the price about 7 basis points on a median session, the implied bid-ask spread works out at about 1.12% of price, the stock traded on 100% of the last year's sessions. Those are estimates from daily closes and volumes, not from the order book, and they describe normal sessions rather than the one session an order has to clear.

What is ABOT's beta?

ABOT's one-year beta against the KSE-100 is 0.78 (correlation 0.70), measured on daily closes to 20 Nov 2026. Its annualised volatility is 20% over 30 days and 19% over 90; the worst peak-to-trough fall in the last year was −33.5%.

Who is the CEO of Abbott Laboratories (Pakistan)?

The CEO of Abbott Laboratories (Pakistan) (ABOT) is Syed Anis Ahmed (PSX company page, 11 Nov 2026).

Who is the chairperson of Abbott Laboratories (Pakistan)?

The Chairperson of Abbott Laboratories (Pakistan) (ABOT) is Ehsan A. Malik (PSX company page, 11 Nov 2026).

Where is the head office of Abbott Laboratories (Pakistan)?

The head office of Abbott Laboratories (Pakistan) (ABOT) is at Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi, Pakistan (PSX company page, 11 Nov 2026).

Who is the auditor of Abbott Laboratories (Pakistan)?

The auditor of Abbott Laboratories (Pakistan) (ABOT) is EY Ford Rhodes, Chartered Accountants (PSX company page, 11 Nov 2026).

Who is the share registrar of Abbott Laboratories (Pakistan)?

The share registrar of Abbott Laboratories (Pakistan) (ABOT) is FAMCO Share Registration Services (Pvt) Limited, 8-F, Next to Hotel Faran, Nursery Block 6, P.E.C.H.S, Shahrah-e-Faisal,Karachi (PSX company page, 11 Nov 2026).

When does the financial year of Abbott Laboratories (Pakistan) end?

The financial year of Abbott Laboratories (Pakistan) (ABOT) ends in December (PSX company page, 11 Nov 2026).

How many shares of Abbott Laboratories (Pakistan) are outstanding?

Abbott Laboratories (Pakistan) (ABOT) has 97,900,302 shares outstanding (PSX company page, 11 Nov 2026).

What is the free float of Abbott Laboratories (Pakistan)?

The free float of Abbott Laboratories (Pakistan) (ABOT) is 21.6% of its shares (PSX company page, 11 Nov 2026).

Which PSX indices include Abbott Laboratories (Pakistan)?

As of 20 Nov 2026, PSX index data lists Abbott Laboratories (Pakistan) (ABOT) in the All-Share, KMI All-Share and KSE-100 indices and 1 other PSX index.

What does Abbott Laboratories (Pakistan) do?

The company profile on PSX (11 Nov 2026) reads: Abbott Laboratories (Pakistan) Limited is a public limited company incorporated in Pakistan on July 02, 1948. The Company is principally engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products.

Answers use the facts on this page. Prices are as of 20 Nov 2026.

12SourcesGuides, filings and sources

Guides for ABOT

Plain explanations of the figures on this page.

Filings and reports

Abbott Laboratories (Pakistan) filings and reports

58 documents Abbott Laboratories (Pakistan) has published — annual reports, quarterly accounts and briefing decks. PSX filings are marked PSX; the rest come from the company’s own investor relations page (visit it). Links open the original PDF at the source.

Filings in SuperX Apex

Sources and dates

FiguresSourceAs of
ReturnsPSX daily closes, KSE-100 closes20 Nov 2026
DividendsPSX payout notices, bonus and rights records18 Nov 2026
ResultsAccounts filed with PSX30 Sep 2026
Cash flow, Borrowings and cash, Ratios, Tests on the accountsThe filed annual report31 Dec 2025
OwnersThe annual report31 Dec 2025

Each row’s date is the latest one its figures stand at.

Data from PSX via SuperX, delayed and provided for information only — not investment advice. Figures may contain errors; verify with your broker before acting. As of .

Track ABOT in your portfolio, from 23 December

Trade logging, price alerts and smart-money flows for PSX investors. Join the waitlist and we email once, when it is ready.

SuperX is not a broker and not an adviser. It never places an order and never asks for a broker login.

Get early access, free